Condition: Recurrent High Grade Glioma · Sponsor: Beijing Tiantan Hospital
This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients. The main questions it aims to answer are: * The LITT would increase the progression-free survival and overall survival of rHGG patients compared to other treatments. * The LITT is safe and applicable to rHGG patients Participants will be randomized to the intervention group (LITT) or control group at a ratio of 2:1. The intervention group patients will receive LITT. The control group will be treated with any other treatment. The primary outcome of this trial is progression-free survival. The estimated sample size is 135, 90 in the LITT group and 45 in the control group.
This description comes directly from the study's public registry record.
Yunke Li, MD · 0086-010-67088936 · liyunke@sinovationmed.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Tsinghua Changgung Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Tongji Hospital | Wuhan, Hubei, China | Recruiting |
| The First Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| The Peoples Hospital of Liaoning | Shenyang, Liaoning, China | Recruiting |
| Qilu Hospital | Jinan, Shandong, China | Recruiting |
| Huashan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06161610